Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic (MDT) announced that its Stealth AXiS surgical system and the Corsano multi-parameter wearable were named TIME Best Inventions of 2026. TIME editors assess the annual list of new products and ideas.
Stealth AXiS combines surgical planning, navigation and robotic-assisted execution within Medtronic's AiBLE ecosystem, supporting spinal, cranial and ear, nose and throat procedures. The Corsano wearable captures vital signs and trending data for patient monitoring from hospital to home. It is manufactured by Corsano Health and distributed by Medtronic in the U.S. and Western Europe.
MiniMed (MMED) completed its separation from Medtronic (MDT), marking its first day as a fully independent company.
Medtronic accepted 55,032,401 ordinary shares in exchange for 252,813,348 MiniMed common shares and no longer holds an equity stake in MiniMed. The exchange offer was 5.4x subscribed.
Medtronic (NYSE: MDT) has completed its separation of MiniMed Group, ending its remaining ownership through a share exchange offer. Medtronic elected to exchange all 252,813,348 MiniMed common shares it still held for outstanding Medtronic ordinary shares. The exchange offer was 5.4x subscribed. MiniMed trades under Nasdaq: MMED, and accepted tendering shareholders will receive MiniMed shares in book-entry form.
Medtronic (MDT) announced final results of its oversubscribed exchange offer and elected to exchange its entire remaining MiniMed (MMED) stake.
Medtronic will exchange 252,813,348 MiniMed shares for 55,032,401 Medtronic ordinary shares. The final proration factor is 18.289133%, except for eligible odd-lot tenders. The offer expired October 9, 2026. After completion, Medtronic will hold no MiniMed common shares.
Medtronic (MDT) announced preliminary results showing its MiniMed exchange offer was oversubscribed after expiring on October 9, 2026. Medtronic intends to accept 55,032,401 ordinary shares in exchange for its remaining 252,813,348 MiniMed shares, at 4.5939 MiniMed shares per accepted Medtronic share. Approximately 18.3% of tendered shares are estimated to be exchanged, subject to guaranteed deliveries. Medtronic expects the final proration factor on October 14, 2026.
Medtronic (NYSE: MDT) set the final exchange ratio for its MiniMed split-off at 4.5939 MiniMed shares per accepted Medtronic share. The offer covers up to 225,361,295 MiniMed shares. If oversubscribed, Medtronic currently intends to exchange its remaining interest as well, adding 27,452,053 shares without extending the offer period. The offer and withdrawal rights expire at midnight, New York City time, at the end of October 9, 2026, unless extended or terminated.
Medtronic (MDT) received American Medical Association approval for Category I procedure codes covering its Altaviva and Symplicity Spyral systems.
The permanent Current Procedural Terminology (CPT) codes replace existing Category III codes effective January 2028. Altaviva treats urge urinary incontinence and received FDA approval in September 2025 for patients who failed or could not tolerate more conservative treatments. Symplicity Spyral treats uncontrolled hypertension; its Medicare coverage was finalized in October 2025. Category I codes can support physician payment and inform commercial payer coverage decisions, but do not determine coverage, reimbursement, clinical superiority or patient access.
Medtronic (MDT) obtained FDA clearance and CE Mark for its latest Affera Prism-2 Mapping Software used in cardiac ablation procedures. It also obtained CE Mark for the PulseSelect ProxBox Adapter with Proximity Indicator software.
Prism-2 helps physicians map the heart's electrical activity while treating abnormal heart rhythms. Its enhancements include heartbeat comparison tools, marking of pacing locations and improvements to the internal pacing stimulator. The PulseSelect adapter adds real-time feedback based on electrical impedance to help physicians assess whether the catheter is near targeted heart tissue before delivering energy.
Medtronic (MDT) received FDA clearance for the LigaSure™ RAS Maryland jaw instrument on its Hugo™ robotic-assisted surgery (RAS) system.
The decision adds Medtronic’s LigaSure vessel-sealing technology to the Hugo RAS instrument portfolio for U.S. robotic-assisted procedures. The LigaSure RAS Maryland device, used with the Valleylab™ FT10 energy platform, seals and cuts vessels, thick tissue, and lymphatics up to 7 mm in diameter in approximately 2 seconds while aiming to minimize thermal spread. It is the first robotic-driven LigaSure instrument and is based on technology used in more than 45 million procedures across over 65 countries. The device was previously introduced on the Hugo RAS system in Europe in 2025 following CE Mark.
MiniMed (MMED) filed a Form S-4 registration statement with the SEC on September 14, 2026, supporting Medtronic’s (MDT) exchange offer for MiniMed shares.
The offer covers up to 225,361,295 MiniMed shares, representing 80.1% of MiniMed’s outstanding common stock, to be exchanged for Medtronic ordinary shares that are validly tendered and not validly withdrawn. If oversubscribed, Medtronic intends to exchange its remaining 27,452,053 MiniMed shares without extending the offer period. Medtronic currently owns approximately 89.86% of MiniMed, and if the exchange offer and related transactions are completed, Medtronic will no longer hold an equity stake in MiniMed.